Media stories about Akcea Therapeutics (NASDAQ:AKCA) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akcea Therapeutics earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.4625232211477 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Akcea Therapeutics (NASDAQ AKCA) traded up $0.97 during trading hours on Wednesday, reaching $20.61. 180,781 shares of the company were exchanged, compared to its average volume of 314,822. The company has a market capitalization of $1,350.00 and a PE ratio of -6.45. Akcea Therapeutics has a 12-month low of $8.10 and a 12-month high of $31.23.
AKCA has been the topic of a number of research reports. BidaskClub raised shares of Akcea Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 31st. Zacks Investment Research raised shares of Akcea Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Tuesday, January 2nd. Stifel Nicolaus downgraded shares of Akcea Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 price target on the stock. in a research note on Tuesday, February 27th. Cowen downgraded shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 27th. Finally, Wells Fargo & Co downgraded shares of Akcea Therapeutics from an “outperform” rating to a “market perform” rating and set a $27.00 price target on the stock. in a research note on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $24.00.
About Akcea Therapeutics
Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.